Clinical Outcomes of Intensive Versus Less Intensive First-Line Chemotherapy for Metastatic Colorectal Cancer

Kentaro Yamazaki1 Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka411-8777, JapanCorrespondence[email protected]

https://orcid.org/0000-0001-6269-9345

Satoshi Yuki2 Department of Gastroenterology & Hepatology, Hokkaido University Hospital, Kita-15, Nishi-7, Kita-ku, Sapporo060-8638, Japan

Eiji Oki3 Department of Surgery & Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka812-8582, Japan

Fumikazu Sano4 Medical Affairs Division, Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo103-8324, Japan

Misako Makishima4 Medical Affairs Division, Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo103-8324, Japan

Kenichi Aoki4 Medical Affairs Division, Chugai Pharmaceutical Co., Ltd, 1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo103-8324, Japan

Tetsutaro Hamano5 P4 Statistics Co., Ltd, Todoroki, Setagaya-ku, Tokyo158-0082, Japan

Kouji Yamamoto6 Department of Biostatistics, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama236-0004, Japan

show all

Clinical Outcomes of Intensive Versus Less Intensive First-Line Chemotherapy for Metastatic Colorectal Cancer

Table S1. Patient characteristics and Barthel indexscores

Table S2. Patient characteristics in the with- and without-molecularly-targeted agent (MTA)subgroups.

Table S3. Patient characteristics in the IT (intensive therapy) and LIT(less-intensive therapy) subgroups.

Supplementary Material

Supplementary Material

Supplementary Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinical Outcomes of Intensive Versus Less Intensive First-Line Chemotherapy for Metastatic Colorectal Cancer

Table S1. Patient characteristics and Barthel indexscores

Table S2. Patient characteristics in the with- and without-molecularly-targeted agent (MTA)subgroups.

Table S3. Patient characteristics in the IT (intensive therapy) and LIT(less-intensive therapy) subgroups.

Supplementary Material

Supplementary Material

Supplementary Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date